Stay updated on UCART123v1.2 in AML Relapse/Refractory - Clinical Trial

Sign up to get notified when there's something new on the UCART123v1.2 in AML Relapse/Refractory - Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the UCART123v1.2 in AML Relapse/Refractory - Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:25:27.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update or revision in the study details related to the safety and efficacy evaluation of UCART123v1.2 in patients with relapsed/refractory acute myeloid leukemia (AML).
    Difference
    0.1%
    Check dated 2024-06-06T14:27:10.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for patients with relapsed or primary refractory AML, specifying conditions such as bone marrow blasts percentage and CD123+ blast cells, among other health and treatment-related criteria.
    Difference
    16%
    Check dated 2024-05-22T21:24:36.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T23:11:21.000Z thumbnail image

Stay in the know with updates to UCART123v1.2 in AML Relapse/Refractory - Clinical Trial

Enter your email address, and we'll notify you when there's something new on the UCART123v1.2 in AML Relapse/Refractory - Clinical Trial page.